Avelumab and Merkel Cell Carcinoma: Causation, FDA Warning, and Clinical Implications

From General Health to Targeted Risk: The Shift in Focus

For decades, public health communication has centered on general wellness principles—diet, exercise, and routine screening—to mitigate broad disease risks. This foundational framework, while valuable, often operates at a population level, leaving nuanced individual risk factors underexplored. As medical science advances, the focus naturally narrows from universal advice to specific exposures that may carry distinct hazard profiles. One such area of emerging scrutiny involves therapeutic agents themselves, particularly when their use extends beyond traditional indications. In the context of oncology, the introduction of immunotherapies like avelumab has transformed treatment paradigms, yet post-marketing surveillance has raised questions about unintended consequences. Specifically, regulatory bodies have issued warnings regarding avelumab and its association with Merkel cell carcinoma, a rare but aggressive skin cancer. This signals a critical pivot: from general health maintenance to the occupational and clinical realities of drug exposure. For healthcare workers, pharmacists, and patients handling or receiving avelumab, the concern shifts from abstract wellness to concrete risk management. The legacy of general health information now must accommodate a more targeted inquiry: how does exposure to this biologic agent, in clinical or occupational settings, correlate with carcinogenic potential? This transition reframes the conversation, demanding vigilance not only in treatment decisions but also in workplace safety protocols.

Avelumab: Mechanism, Approval, and Clinical Evidence

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a highly aggressive skin cancer with neuroendocrine differentiation, and its incidence is rising (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by ultraviolet light exposure leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The standard treatment for metastatic MCC involves the use of anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab or pembrolizumab, which, compared with conventional chemotherapy, show better overall response rates and longer duration of responses (https://pubmed.ncbi.nlm.nih.gov/34445385/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors do not respond or progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). Additionally, some patients develop immune-related adverse events due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).

Risk Context: Treatment Failure and Alternative Strategies

For patients who become refractory to avelumab, efficient and safe treatment options are limited (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study conducted at three academic sites in Germany, five patients with metastatic MCC refractory to avelumab were subsequently treated with combined ipilimumab and nivolumab (IPI/NIVO). Three out of five patients responded to this combination therapy according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study from the prospective skin cancer registry ADOREG similarly reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study noted that despite the advances in systemic therapy for MCC, approximately 50% of patients treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). From a risk perspective, the adequacy of warnings regarding avelumab and Merkel cell carcinoma is centered on its approved indication for metastatic MCC. The FDA warning for avelumab is not specifically about causing MCC; rather, the drug is indicated for treating MCC. The evidence does not suggest that avelumab causes Merkel cell carcinoma; instead, it is a therapeutic agent used to treat the disease. The primary risk for patients is the potential for lack of response or progression while on avelumab therapy, as well as the development of immune-related adverse events. The timeline between exposure to avelumab and documented harm is typically measured in terms of treatment cycles, with response assessments often conducted after several weeks or months. For patients who do not respond, the harm is the progression of MCC, which can occur during or after avelumab treatment. The evidence indicates that approximately 50% of patients may not respond or may progress, highlighting the need for alternative therapies such as combination immunotherapy with ipilimumab and nivolumab (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/35877101/). Causation-related considerations for affected patients involve understanding that avelumab is not a causative agent for MCC but rather a treatment. The harm associated with avelumab is primarily related to treatment failure or adverse events, not the induction of the disease itself. The evidence supports that avelumab is effective in a subset of patients, but a significant proportion do not benefit. For those patients, the risk is disease progression, which may require alternative management strategies. The timeline between avelumab exposure and harm is variable, depending on individual patient factors and tumor biology. In summary, avelumab is an approved therapy for metastatic Merkel cell carcinoma, with evidence of efficacy in approximately one-third of chemotherapy-refractory patients. However, about half of patients do not respond or progress on therapy, necessitating further treatment options. The FDA warning for avelumab pertains to its use as a treatment, not as a cause of MCC. The risk narrative for patients involves the potential for non-response or progression, as well as immune-related adverse events, with timelines varying based on individual treatment courses.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma, not a cause. The FDA warning for avelumab relates to its use as a therapy for metastatic MCC, not as a causative agent. The evidence indicates that avelumab is effective in about one-third of chemotherapy-refractory patients, but approximately 50% of patients may not respond or may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/).

What are the risks associated with avelumab treatment?

The primary risks include lack of response or disease progression while on avelumab, as well as immune-related adverse events. Approximately 50% of patients with advanced MCC do not respond or progress on immune checkpoint inhibitors (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). Alternative therapies, such as combination ipilimumab and nivolumab, may be considered for refractory cases (https://pubmed.ncbi.nlm.nih.gov/33439294/).

What is the timeline for harm from avelumab exposure?

The timeline is variable and measured in treatment cycles, with response assessments typically after several weeks or months. Harm may manifest as disease progression during or after avelumab treatment, or as immune-related adverse events that can occur at any time during therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.